Healthcare [ 5/13 ] | Biotechnology [ 50/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 30, 23 | -0.83 Decreased by -1.22% | -0.65 Decreased by -27.69% |
| Nov 13, 23 | -0.83 Decreased by -1.22% | -0.65 Decreased by -27.69% |
| Aug 10, 23 | -0.56 Increased by +37.78% | -0.81 Increased by +30.86% |
| Mar 31, 23 | -1.18 Decreased by -57.33% | -0.73 Decreased by -61.64% |
| Feb 28, 23 | -0.82 Increased by +31.67% | -0.73 Decreased by -12.33% |
| Nov 8, 22 | -0.82 Increased by +21.9% | -0.91 Increased by +9.89% |
| Aug 9, 22 | -0.9 Decreased by -20% | -0.85 Decreased by -5.88% |
| Mar 21, 22 | -0.75 Decreased by -66.67% | -1.27 Increased by +40.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Aug 31, 23 | 0 Decreased by N/A% | -2.45 M Decreased by -8.31% | Decreased by N/A% Decreased by N/A% |
| May 31, 23 | 0 Decreased by N/A% | -1.6 M Increased by +34.12% | Decreased by N/A% Decreased by N/A% |
| Feb 28, 23 | 0 Decreased by N/A% | -3.2 M Decreased by -61.24% | Decreased by N/A% Decreased by N/A% |
| Nov 30, 22 | 0 Decreased by N/A% | -3.34 M Decreased by -31.04% | Decreased by N/A% Decreased by N/A% |
| Aug 31, 22 | 0 Decreased by N/A% | -2.26 M Decreased by -19.84% | Decreased by N/A% Decreased by N/A% |
| May 31, 22 | 0 Decreased by N/A% | -2.43 M Decreased by -7.88% | Decreased by N/A% Decreased by N/A% |
| Feb 28, 22 | 0 Decreased by N/A% | -1.98 M Decreased by -6.33% | Decreased by N/A% Decreased by N/A% |
| Nov 30, 21 | 0 Decreased by N/A% | -2.55 M Decreased by -77.6% | Decreased by N/A% Decreased by N/A% |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.